Kornimate/medical-research-clean huggingface dataset:
study to determine if atorvastatin reduces size and stiffness of muscle in the left ventricle of the heart

Conditions: Hypertrophic Cardiomyopathy

Summary: the purpose of this study is to determine if a drug called atorvastatin will reduce the size and stiffness of the muscle in the left ventricle of the heart.

hypertrophic cardiomyopathy (hcm) is a primary disorder of the heart characterized by a thickened, fibrotic myocardium, with or without a dynamic left ventricular outflow tract gradient. it is a common heritable cardiovascular disease, with a population prevalence of 0.1% to 0.2%. symptoms of congestive heart failure are extremely common in patients with hcm. progression to disabling and debilitating symptoms \[new york heart association (nyha) class iii and iv\] is relatively common, occurring in 15% to 20% of unselected populations. the rate of progression to nyha class iii or iv or death from heart failure or stroke is high, with a relative risk 2.7. management of symptoms can be very challenging, involve multiple medications, and 5% of patients may develop drug refractory heart failure, requiring invasive intervention. hcm is the most common cause of sudden death among young competitive athletes. ventricular tachyarrhythmias appear to be the primary mechanism; however, other arrhythmias involved include asystole, rapid atrial fibrillation, and electrical mechanical dissociation. patients may develop progressive myocardial wall thinning, a reduction in systolic performance, and an increase in left ventricular dimensions. progressive wall thinning may be especially common in patients with initially severe hypertrophy. there is no cure for this condition. there is now evidence from both animal and human studies of a treatment that promises to reverse hypertrophy - hmg coa reductase inhibitors. clearly, studies of treatments that might cause regression of hypertrophy are timely and important.

Eligibility criteria:
inclusion criteria: * 18 years and over with hcm in the absence of another cardiac or systemic disease capable of producing a prespecified wall thickening exclusion criteria: * required use of statin therapy or intolerance * a clinical diagnosis of hypertension * indication for statin therapy for primary or secondary prevention of coronary artery disease * current or anticipated indication in ≤ 1 year for implantable cardioverter defibrillators or other metallic devices preventing cardiac magnetic resonance imaging (mri).

Keywords: hypertrophic cardiomyopathy statin therapy regression heart failure arrhythmias sudden cardiac death
cipn and it's impact on quality of life in patients receiving platinum and taxanes

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: neuropathies are a major cause of moderate to severe impairments in cancer patients. chemotherapy-induced peripheral neuropathy (cipn) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%.

neuropathies are a major cause of moderate to severe impairments in cancer patients . chemotherapy-induced peripheral neuropathy (cipn) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. there are six main substance groups that cause damage to neurons developing cipn: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). platinum-based chemotherapeutics (oxaliplatin, cisplatin and carboplatin) have the highest prevalence rates of cipn, affecting \~ 70% of patients, often complicated by coasting acute oxaliplatin-induced peripheral neuropathy (oipn) can result in prolonged infusion times (\~ 22%), dose reduction (15-43%) and treatment cessation (6-21.4%) taxane-induced peripheral neuropathy (tipn) (paclitaxel, docitaxel and cabazitaxel ) is the most common non-haematological adverse event of treatment,however, docetaxel is generally considered to be less neurotoxic than paclitaxel. cipn occurs in a dose-dependent manner usually ,duration of exposure, scheduling and combination therapies are also potential risk factors. diabetes mellitus and increasing age (≥75 years) have been proposed as strong independent risk factors(9). in addition to ,alcohol abuse, renal insufficiency, hypothyroidism, infections like (hiv) and smoking. the severity of neuropathies can be graded by (grading scales of cipn includes; national cancer institute common terminology criteria for adverse events (nci-ctcae) most commonly used , who grading system ,self-assessment by patients is preferable due to consistent underrating by healtcare professionals. symptoms of cipn in hands and feet, such as tingling, numbness, cramps can cause problems with regular daily activities , standing and walking , patients became limited in their daily activities and number of them stated that they became more dependent on others. treatment strategies depends on discontinuation or lowering the dose . persistent neuropathic pain can be treated with anti-seizure medications, antidepressants, or analgesics . in severe painful conditions patients may be referred to the chronic pain clinic.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and \<75 . * sex : male or female * adjuvant or metastatic * receiving neurotoxic agents " platinum and taxanes " * no documentation of any other causes of neuropathy in their medical records as : congenital and dm exclusion criteria: * pt not receiving any neurotoxic cth. * detected other causes of neuropathy.
taurine in peripartum cardiomyopathy

Conditions: Peripartum Cardiomyopathy

Summary: taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy


Eligibility criteria:
inclusion criteria: * peripartum cardiomyopathy exclusion criteria: * other identifiable cause for heart failure * low lvef ≤ 25% * sepsis * autoimmune disease * severe chronic disease * malignancy
the impact of hafnia alvei on weight loss and glycaemic control after bariatric surgery

Conditions: Obesity; Type 2 Diabetes

Summary: this study aims to investigate the effects of hafnia alvei ha4597 tm supplementation on weight loss and glycemic control after bariatric surgery. patients undergoing roux-en-y gastric bypass will receive probiotics or placebo, twice a day, for 90 days, one month after surgery. outcomes will be measured at baseline, and 3, 6, 9 and 12 months after the surgery.

gut microbiota dysbiosis is associated with the pathophysiology of obesity. bariatric surgery is an effective treatment for obesity that induces changes in the gut microbiota. however, recent studies indicate that the gut microbiota is not fully restored after bariatric surgery which may limit the potential of the surgery to achieve metabolic control and maintain weight loss. thus, modulating the gut microbiota with probiotics after bariatric surgery could be an effective strategy to improve the success of the surgery. this study aims to investigate the effects of hafnia alvei ha4597 tm supplementation on weight loss and glycemic control after bariatric surgery. patients undergoing roux-en-y gastric bypass will receive probiotics or placebo, twice a day, for 90 days, one month after surgery. outcomes will be measured at baseline, and 3, 6, 9 and 12 months after the surgery.

Eligibility criteria:
inclusion criteria: * men and women between 18 and 65 years * bmi ≥35 kg/m2 and at least one severe obesity-related complications, or bmi ≥40 kg/m2 * undergoing roux-en-y gastric bypass * willing to take a probiotic/placebo supplement twice a day for 60 days * willing and able to provide written informed exclusion criteria: * intake of antibiotics and/or probiotics in the previous 12 weeks * weight change \>5% in the previous 12 weeks * diagnosis of gastrointestinal disease or other significant illness * pregnancy or breastfeeding

Keywords: obesity gut microbiota probiotics
bosentan in children with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (pah) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that in adults with pah and to evaluate the tolerability and safety of a pediatric formulation of bosentan in this patient population.


Eligibility criteria:
inclusion criteria: * signed informed consent by the parents or the legal representatives. * males or females \>= 2 and \< 12 years of age. * idiopathic pah or familial pah diagnosed by right heart catheterization (clinical classification of pulmonary hypertension, venice 2003). * world health organization (who) functional class ii or iii. * oxygen saturation (spo2) \>= 88% (at rest, on room air). * pah treatment-naïve patients or patients already treated with either: * bosentan monotherapy * intravenous epoprostenol monotherapy * intravenous or inhaled iloprost monotherapy * combination of bosentan and intravenous epoprostenol * combination of bosentan and intravenous or inhaled iloprost. * all patients should start the study drug (bosentan pediatric formulation) at 2 mg/kg twice daily (b.i.d.), whether or not they were previously treated with bosentan. * pah therapy stable for at least 3 months prior to screening. * stable treatment with calcium channel blockers, if any, for at least 3 months prior to screening. * patient's pah condition stable for at least 3 months prior to screening. exclusion criteria: * pah associated with conditions other than idiopathic or familial pah. * non-stable patients, e.g., history (in the last 3 months prior to screening) of recurrent syncope, or signs and symptoms of non-compensated right heart failure. * need or plan to wean patients from intravenous epoprostenol, or intravenous, or inhaled iloprost. * body weight \< 4 kg. * systolic blood pressure \< 80%, the lower limit of normal range, according to age and gender. * ast and/or alt values \> 3 times the upper limit of normal ranges. * moderate to severe hepatic impairment, i.e., child-pugh class b or c. * hemoglobin and/or hematocrit levels \< 75% of the lower limit of normal ranges. * pregnancy. * known intolerance or hypersensitivity to bosentan or any of the excipients.

Keywords: bosentan children pharmacokinetics pulmonary arterial hypertension
valeria: valsartan in combination with lisinopril in hypertensive patients with microalbuminuria

Conditions: Hypertension

Summary: the purpose of this study is to compare if the combination of valsartan 320 mg/lisinopril 20 mg versus the monotherapies of lisinopril 40 mg or valsartan 320 mg will result in a greater decrease of urinary albumin excretion measured as urinary albumin/creatinine ratio (uacr) in the first morning urine of hypertensive subjects with previously diagnosed microalbuminuria (mau).


Eligibility criteria:
inclusion criteria: * patients with mild to moderate hypertension with a mean sitting diastolic blood pressure (msdbp) \> 85 and \< 110 mmhg for non-treated patients. previously treated patients with msdbp \< 110 mmhg. treated is defined as having taken medication until \< 2 days prior to visit 1 * positive urine spot test with micral dipstick (detection of urinary albumin concentration of at least 50 mg/l) at visit 1 (day -21). * confirmation of mau of at least 2 out of 3 measurements determined in the first morning urine samples performed at visit 1 day-21), visit 2 (day -14) or visit 3 (day -7). mau is defined for male patients as urinary albumin creatinine ratio (uacr) \> 2.5 mg/mmol and \ 3.5 mg/mmol and \< 35.0 mg/mmol at both visits. exclusion criteria: * evidence of renal impairment as determined by any one of the following: * serum creatinine clearance \< 30 ml/min as determined by cockroft and gault formula \[cockroft and gault, 1976\] and/or * serum creatinine \> 1.25 x uln at visit 1, * a history of dialysis, or * a history of nephrotic syndrome. * serum potassium values \ 5.5 mmol/l at visit 1 * any medical condition which might significantly alter the urinary excretion of albumin other protocol-defined exclusion criteria may apply.

Keywords: microalbuminuria, urinary albumin excretion, urinary albumin creatinine ratio, hypertension, valsartan, lisinopril, combination
preliminary administration of epo and markers of cardiac ischemia induced by cpb

Conditions: Myocardial Ischemia

Summary: the main objective is to observe the effects of erythropoietin administration on different blood markers of ischaemic cardiac lesions induced by cardiopulmonary bypass.

a new property of erythropoietin (epo), independent of its hematopoietic role, has recently been discovered. indeed, it has been reported that this hormone, following binding to its cardiac or cerebral receptors, is able to induce a spectacular cellular protection against ischemic injury. these cardioprotective and neuroprotective effects have been observed experimentally in rodents as well as clinically in humans. in particular, our team has demonstrated that the administration of neorecormon® protects the heart against ischemia in the rat by significantly improving its recovery. in view of these exciting experimental results and of the growing interest of the scientific community for cytoprotective effects of epo, we are planning the first clinical study examining the cardiac and cerebral protective effects of epo (neorecormon®) in the setting of cardiac surgery.

Eligibility criteria:
inclusion criteria: * coronary bypass surgery. * surgery not urgent. * left ventricular ejection fraction (lvef) \> 40. * informed consent form signed. exclusion criteria: * valvular surgery. * surgery with beating heart, with or without cardiopulmonary bypass. * carotid bypass surgery. * myocardial infarction less than 30 days. * previous history of cardiac surgery. * kidney failure (creatinine \> 200 µmol/l). * uncontrolled hypertension. * unstable angina. * risk of deep venous thrombosis. * vascular cerebral attack less than 30 days. * malignant tumour. * phenylketonuria. * allergy to erythropoietin. * previous programmed blood donation. * pregnancy and feeding.

Keywords: troponin t ck-mb protein s-100 cardiopulmonary bypass erythropoietin
efficacy of the recovery workbook as a psychoeducational tool for facilitating recovery

Conditions: Mental Disorders

Summary: the present study will determine if spaniol and colleague's (1994) recovery workbook group intervention is an effective clinical tool to move a person with smi along in their journey of recovery. the primary outcome measurements of this study will be the participants' perceived level of empowerment, hope and optimism, knowledge of recovery, and life satisfaction. this kind of information would add to the current body of knowledge about how principles of recovery can be used in psychoeducational programs used by outpatient community mental health services.

abstract: objective: adopting the principles of recovery into the mental health field has been a growing area for discussion at many different levels of care. the present study will determine if spaniol and colleague's (1994) recovery workbook group intervention can be used as an effective clinical tool to move a person with a severe mental illness along in their journey of recovery. the primary outcome measurements of this study will be the participants' perceived level of empowerment, hope and optimism, knowledge of recovery, and life satisfaction. method: the study will be a multicenter, prospective, single-blinded, randomized control trial. sixty participants will be recruited from three assertive community treatment teams (actt) in kingston, ontario and individuals will be randomized to either the control or intervention arm of the study. the control arm of the study will receive their regular services from actt. the intervention arm will participate in a 10-week psychoeducational group program in addition to receiving their regular services from actt. results: analysis will be performed by intention to treat, based on total scores of four assessments which will be performed at the trial commencement and termination.

Eligibility criteria:
inclusion criteria: 1. receive support from an assertive community treatment team. 2. meet the dsm-iv diagnostic classification for schizophrenia, schizoaffective, schizophreniform, delusional disorder, or bipolar disorder. 3. aged 18-55 years-old. 4. individuals agree to participate in the study after they have been informed of all the expected benefits and risks. 5. neither substance misuse nor organic disorder judged to be the major cause of psychotic symptoms. exclusion criteria: 1. inability to give informed consent 2. diagnosis of dementia 3. significant head injury or other brain injury leading to cognitive impairment 4. mental retardation (premorbid iq \< 65) 5. require an interpreter

Keywords: recovery, hope, empowerment, randomized control trial
the prognostic role of tricuspid annular plane systolic excursion in critically ill patients with septic shock

Conditions: Septic Shock

Summary: the aim of this study is to evaluate the possible prognostic performance of rv dysfunction, as assessed by tapse, in non-cardiac patients with septic shock.

the objective is to investigate the prognostic performance of right ventricular dysfunction, as assessed by tricuspid annular plane systolic excursion (tapse), in non-cardiac patients with septic shock.

Eligibility criteria:
inclusion criteria: * adult patients (18 - 64 years old) with septic shock after admission according to 2016 consensus definition (sepsis-3). exclusion criteria: * pregnant females * trauma * documented coronary heart disease * history of myocardial infarction * myocarditis * thrombo-embolic pulmonary disease * valvular heart disease * corpulmonale * arrhythmia * known left ventricular ejection fraction \< 40% * poor echocardiographic window

Keywords: critical care septic shock echocardiography rv dysfunction
the multi-center study of shear wave elastography on thyroid nodules

Conditions: Thyroid Nodules

Summary: the incidence rates of thyroid cancers have increased in the past decade. additionally, up to 68% of people have thyroid nodules. consequently, a precise evaluation of thyroid nodules is very important and can avoid unnecessary biopsy of benign nodules. shear wave elastography(swe), a novel ultrasound-based elastographic method, is a new real-time, quantitative, operator-independent, and reproducible technique. briefly, shear wave elastography uses a radiation force produced by an ultrasonic beam to stress tissues and ultrafast sonographic tracking techniques to measure the speed of shear waves. based on the young modulus formula, tissue elasticity can be derived from the shear wave propagation speed, and a real-time color-coded elastogram can be displayed, showing softer tissue in blue and stiffer tissue in red. there are lots of research confirmed that swe has a certain value in the diagnosis of thyroid carcinoma. these studies include prospective studies and retrospective studies, but both belong to a single center study. it has not been applied to the study of the multicenter of thyroid disease. the main purpose of the study is to assess the performance of swe for identification of benign and malignant thyroid nodules and calculate the optimal cutoff value for each parameter in multicenter study; the secondary purpose is to evaluate the application value of swe for uncertain nodules by fna.

swe can prove the diagnostic performance in the differentiation of benign and malignant thyroid lesions 1. main purpose 1. to assess the performance of swe for identification of benign and malignant thyroid nodules in multicenter study; 2. calculate the optimal cutoff value for each parameter in multicenter study 2. secondary purpose to evaluate the application value of swe for uncertain nodules by fna.

Eligibility criteria:
inclusion criteria 1. the size of the lesion is between 0.5～4cm 2. the solid components in the lesion\>50%； 3. all patients perform fna or surgery in one month after swe examination exclusion criteria: 1. patients who are unwilling or unable to provide informed consent 2. woman who is pregnant or breastfeeding; 3. thyroid nodules with calcified which is beyond 1/2 diameter of lesion 4. patients who have history of surgery、fna or thermal ablation in ipsilateral thyroid 5. patients who have serious cardiopulmonary diseases

Keywords: swe diagnosis
comparison of tramacet versus percocet in post surgical patients

Conditions: Post Operative Pain

Summary: opioid naive patients are randomized to receive either tramacet or percocet at the time of discharge following mild to moderate pain risk surgery. the following will be assessed: 1) brief pain inventory (bpi) for the month. 2) post operative pain management satisfaction. 3) whether they sought any repeat opioid prescription. 4) whether they intend to seek repeat opioid prescription. it is expected that both groups will have similar pain outcomes but those patients in the percocet group will be more likely to seek a second prescription.

patient operating lists will be screened on a daily basis at identify potential patient candidates. the surgeon of note will be consulted to ensure that each patient, in their opinion, may be a candidate. if approved by the surgeon of note, the patient will then be approached in the preoperative area by a member of the research team to determine if they will consent to enrollment in the study. patients will be double blinded and randomized following low to moderate pain surgery (surgery in which patients do not generally require a patient controlled analgesic pump post-operatively, or require post operative analgesia beyond 14 days) to receive either tramacet 1-2 tablets orally every 4 hours prn or percocet 1-2 tablets orally every 4 prn. at time of discharge patients will recieve unidentifiable tablets in an unidentifying container of the usual dispense amount that their surgeon would standardly prescribe(range is usually between 30 and 60 tabs). at 6 weeks patients will receive a phone call to determine a) brief pain inventory score for the month. b) if they sought a second opioid prescription. c) if they plan to seek a second script. e) satisfaction of post operative pain control on a 1-10 numerical scale f) any adverse side effects.

Eligibility criteria:
inclusion criteria age 18-65 opioid naïve postoperative from mild to moderate pain risk surgery (surgery in which patients do not generally require a patient controlled analgesic pump post-operatively, or require post operative analgesia beyond 14 days) exclusion criteria: patients on opioids children \< 18 years elderly pregnancy language barrier past medical history of psychosis coexisting use of anti-depressants american society of anesthesia risk score \>3 known allergy to opioid or acetaminophen

Keywords: post operative pain addiction